Appeals court revives Tylenol-autism lawsuits, reopening key risk for Kenvue

What happened

A U.S. federal appeals court on Monday revived hundreds of private lawsuits against Kenvue and retailers alleging that Tylenol (acetaminophen) during pregnancy causes autism and ADHD. This reverses earlier dismissals and reopens broad litigation that had been a persistent overhang on KVUE's stock. The decision does not establish liability but increases the probability of settlement costs, reputational damage, and potential FDA regulatory pressure on acetaminophen labeling. For Kenvue, which is in the process of being acquired by Kimberly-Clark, this legal development introduces a new source of deal uncertainty and could widen the merger-arb spread. Management had previously warned that such litigation and FDA actions could depress sales and increase liability, and this ruling validates that risk scenario.

Implication

The revived lawsuits increase the probability of material settlement costs and FDA labeling changes, which could suppress Tylenol revenue and delay or reprice the Kimberly-Clark acquisition. Investors should monitor legal developments and any disclosure of settlement reserves. If the deal closes, post-merger integration costs may rise; if the deal fails, standalone valuation will face additional pressure.

Thesis delta

The investment thesis shifts from a straightforward merger-close instrument with manageable litigation overhang to a situation where the revived Tylenol lawsuits materially threaten deal economics, timing, and standalone value. The 25% probability bear-case scenario has become more likely, as this development could force material remedies, delay foreign approvals, or reduce synergy expectations. The margin of safety narrows, and the re-assessment window should be shortened to 3-6 months to monitor legal and regulatory outcomes.